Skip to content
Companies

Mangrove Therapeutics

Therapies targeting an RNA regulator of inflammation

Raised to date

$2.5M

of $5M offered across 1 Form D filing

Still open
$2.5M
Investors
9
Last filed
Jul 31, 2026

About

Mangrove Therapeutics is a preclinical biotechnology company incorporated in November 2025 and registered in Sacramento, California, with research operations described as based in Stanford, California. It is developing first-in-class therapies aimed at a novel RNA-mediated master regulator of inflammation, a target it describes as a gap in polygenic disease biology. The company pairs AI-informed genetic diagnostics with small molecule and siRNA modalities to modulate the causal pathway mediating immune signaling and inflammation, and to stratify patients for treatment. Research is led by Viktoria Kheifets, previously SVP at Alkahest and a biology group leader at Edison Pharmaceuticals; Benjamin Chen is CEO and Alexander Green is CFO and Secretary.

The company argues that more than 95% of inflammatory disease patients carry polygenic risk that existing therapies cannot mechanistically address, and that its target - an RNA-mediated master regulator validated in human genetics - is a single causal node reachable across multiple high-value inflammatory indications, with AI-informed genetic diagnostics used to pick the patients most likely to respond.

Funding

  • OtherFiled Jul 31, 2026Form D
    $2.5M/ $5M

Product

RNA-mediated inflammation master regulator program

Preclinical therapeutics

A preclinical therapeutic program targeting a novel RNA-mediated master regulator of inflammation, pursued with both small molecule and siRNA approaches to modulate the causal pathway that mediates immune signaling and inflammation in polygenic inflammatory disease.

  • Novel RNA-mediated master regulator of inflammation as the target
  • Dual modality: small molecule and siRNA
  • Human genetics validation of the causal pathway

Built for

Patients with polygenic inflammatory diseases, reached through the clinicians, health systems and pharmaceutical partners that would prescribe or co-develop the therapy

People on file